Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours—A comment on: ‘Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment of brain metastases.’ by Loriot and colleagues

Publication date: May 2018
Source:European Journal of Cancer, Volume 95
Author(s): Constantine Alifrangis, Peter Wilson, Jonathan Shamash




https://ift.tt/2rjeLlc